

German Biotech Sets Record, Seeks Investors

German biotech continues to grow, representing an opportunity for foreign capital

Berlin (GTAI) - Germany's biotech industry pulled in 4.4 billion euros of business in 2018, up 9 percent over 2017, according to Ernst & Young's annual report on the sector. Driving the growth were large publically listed companies, whose turnover grew by 12 percent.

380,000 liters of fermenter capacity puts Germany on top rank in Europe with some 30 biopharmaceuticals produced on site. The number of people employed in German biotech also continued to increase, and a record 1.23 billion euros was invested in research and development.

But there's plenty of room for further expansion. Investment in biotech in Germany lags behind that in the US, as the German newspaper Handelsblatt has pointed out, and German biotech companies often seek venture capital abroad.

"The German biotech sector offers great chances for foreign investors," says Germany Trade & Invest's Chemicals and Health Senior Manager Gabriel Flemming. "Growth is there, and so is the thirst for capital infusions."

For more information about Germany's biotech sector, please see GTAI's fact sheet [HEALTH MADE IN GERMANY. The Medical Biotechnology Sector](#) ▶



Jefferson Chase | © GTAI/
Illing & Vossbeck
Fotografie

CONTACT US

Jefferson Chase

☎ +49 30 200 099 170

✉ [Submit your question](#)

All rights reserved. Any reproduction in whole or part only with express written permission. All efforts are made to ensure integrity of the content, however we are not liable for any mistakes that may occur.

© 2019 Germany Trade & Invest

Promoted by Federal Ministry for Economic Affairs and Energy in accordance with a German Parliament resolution.